Industry news
This week in pharma.
20 stories this week · updates every 30 minutes
pharmaphorum · about 1 hour ago
Gazyva is first FDA-cleared drug for rare disease pMN
Read articlepharmaphorum · about 2 hours ago
AZ's Alexion extends gMG options with two Klygefa approvals
Read articlepharmaphorum · about 3 hours ago
An AAPS PharmSci 360 overview: Making better decisions faster, earlier, with fewer resources
Read articlepharmaphorum · about 4 hours ago
China overtakes Europe in healthcare investing sentiment
Read article
Pharmaceutical Technology · about 4 hours ago
Sofinnova Partners backs European life sciences sector with €725M raise
The main recipients of this fund will be European life sciences companies, though some across the US and other geographies will also benefit.
Read article
Pharmaceutical Technology · about 4 hours ago
AstraZeneca secures FDA approval for Imfinzi combo in MIBC
The US FDA has approved AstraZeneca's Imfinzi in combination with enfortumab vedotin for adult patients with MIBC who cannot receive or have refused cisplatin-based chemotherapy.
Read article
Pharmaceutical Technology · about 5 hours ago
FDA rejects Summit’s ivonescimab application for lung cancer
The US FDA has declined to approve Summit Therapeutics’ BLA for ivonescimab in patients with locally advanced or metastatic NSCLC.
Read articlepharmaphorum · about 5 hours ago
Catching the signals sooner: AI’s role in proactive pharmacovigilance
Read article
Pharmaceutical Technology · about 11 hours ago
HLTH 2026: Potential 2028 US presidential contender Mark Kelly warns pharma over profits
Following the 2026 US midterm elections, Democrats are putting healthcare affordability, drug pricing and insurance coverage at the centre of their agenda. Speaking at HLTH USA in Las Vegas, Senator Mark Kelly also hi…
Read articlepharmaphorum · about 20 hours ago
FDA won't approve Summit, Akeso's ivonescimab
Read article
Pharmaceutical Technology · 3 days ago
AHA26: Boehringer’s survodutide establishes CV safety in SYNCHRONIZE-CVOT
KOLs interviewed by GlobalData were more optimistic about survodutide’s potential in fatty liver disease (MASLD) than weight loss.
Read article
Pharmaceutical Technology · 3 days ago
AHA26: Semaglutide’s real-world CV benefits highlight importance of persistence
Real-world semaglutide CV outcomes mirror clinical trials, with greater treatment persistence linked to better outcomes.
Read articlepharmaphorum · 3 days ago
Closing the global evidence gap in oncology, with Flatiron Health
Read article
Pharmaceutical Technology · 3 days ago
BIO Europe: Financing, AI and geopolitics shape biotech discourse
Speakers at BIO-Europe 2026 noted that European biotechs must be agile and adaptable in times of geopolitical and financial upheaval.
Read articlepharmaphorum · 3 days ago
Windward Bio catches $175m from its IPO
Read articlepharmaphorum · 3 days ago
Neurosterix' $105m round leads the week's biotech financings
Read article
Pharmaceutical Technology · 3 days ago
FDA puts commissioner’s priority voucher framework on ice
Experts consistently questioned how vouchers were awarded, along with critiquing its wider industry benefits.
Read article
Pharmaceutical Technology · 3 days ago
Neurosterix pockets $105m to advance neuropsychiatry pipeline
Neurosterix hopes that NTX-253 may compete with BMS’s Cobenfy as the schizophrenia field explores mechanisms past dopamine modulation.
Read article
Pharmaceutical Technology · 3 days ago
BMS sets unified research and development structure for 2027
Bristol Myers Squibb (BMS) is set to merge its separate research and development (R&D) departments into a single entity, effective from 1 January 2027.
Read articleGet the weekly round-up
Join our mailing list for industry news and Smartcare updates.
Headlines link to their original publishers, including pharmaphorum and Pharmaceutical Technology.
